Use of Xofigo in mCRPC. Preview of a Belgian multidisciplinary consensus publication
Published on 04.04.2018
Dear colleagues, you are cordially invited to regional meetings organised by Bayer with the aim of discussing the use of Xofigo in mCRPC patients and presenting the results of a multidisciplinary consensus about sequences of available treatments for mCRPC patients with a focus on Xofigo.
One meeting is confirmed in Leuven on the 18th of April
the BELNUC board.